CD274 and non-small cell lung carcinoma: Because NSCLC patients will likely receive some form of checkpoint immunotherapy (CIT) targeting PD-1/PD-L1 in the course of their treatment, we also explored the outcome of SMARCA4-mutant patients treated with CIT.